Kidney stones (calculi) are mineral concretions in the renal calyces and pelvis (FIG. 1) that are found free or attached to the renal papillae. By contrast, diffuse renal parenchymal calcification is called nephro calcinosis 1 . Stones that develop in the urinary tract (known as nephro lithiasis or urolithiasis) form when the urine becomes excessively supersaturated with respect to a mineral, leading to crystal formation, growth, aggre gation and retention within the kidneys 2 . Globally, approximately 80% of kidney stones are composed of calcium oxalate (CaOx) mixed with calcium phos phate (CaP). Stones composed of uric acid, struvite and cystine are also common and account for approx imately 9%, 10% and 1% of stones, respectively 3 . Urine can also become supersaturated with certain relatively insoluble drugs or their metabolites, leading to crystal lization in the renal collecting ducts (iatrogenic stones). , >50,000 of whom were hospitalized; six patients died as a result.
. Urine can also become supersaturated with certain relatively insoluble drugs or their metabolites, leading to crystal lization in the renal collecting ducts (iatrogenic stones). For example, patients with HIV who are treated with protease inhibitors such as indinavir and atazanavir are at risk for developing nephrolithiasis 4 . Both indina vir and atazanavir are metabolized by the liver, with a consider able proportion of the drug excreted in the urine unchanged, leading to their crystallization and the for mation of kidney stones 5 . Even when given as part of a multiple drug regimen, atazanavir can crystallize in the urine and form kidney stones 6 . Poorly soluble dietary contaminants can also crystal lize and form stones. For example, melamine has been implicated in the deaths of dogs and cats 7, 8 and caused a major health emergency in China in 2008. Melamine adulteration of infant formula led to the development of stones and sandlike calculi in the urinary tracts of >294,000 infants 9, 10 , >50,000 of whom were hospitalized; six patients died as a result.
Stone formation is a common disease, with an esti mated 5year recurrence rate of up to 50% 11 . The preva lence of stones has been consistently increasing over the past 50 years and further increases are expected owing to changing lifestyle, dietary habits and global warm ing [12] [13] [14] . Obesity 15 , diabetes [16] [17] [18] , hypertension 13, 17, 19 and metabolic syndrome 20 are considered risk factors for stone formation; conversely, stone formers are at risk of hypertension 19, 21 , chronic kidney disease (CKD) and endstage renal disease (ESRD) [22] [23] [24] [25] . The costs associated with stone disease have also risen, increasing from an estimated US$2 billion in 2000 to over US$10 billion in 2006 in the United States alone 26 . Major advances have been made in the medical and surgical management of patients with kidney stones. Stones can be fragmented using shockwave lithotripsy (SWL) to enable them to pass in the urine, or surgically removed using percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS). PCNL involves direct endoscopic access into the kidney through an incision in the flank, whereas RIRS is performed using a flexible fibreoptic ureteroscope to access the upper urinary tract through natural passageways. Medical therapies are being used to ease stone passage, pro mote expulsion and reduce stone recurrence. Important advances have also been made in our understanding of stone pathogenesis. This Primer focuses on the medical and surgical management currently practiced, as well as the contemporary understanding of stone pathogenesis.
Epidemiology
A recent review of epidemiological data from seven countries revealed incidence rates for kidney stones of 114-720 per 100,000 individuals and prevalence rates of 1.7-14.8%, and in nearly all countries, the rates seem to be rising 27 . According to data from the National Health and Nutrition Examination Survey (NHANES), the selfreported prevalence of kidney stones in the United States has increased nearly threefold, from 3.2% in the period 1976-1980 to 8.8% in 2007-2010 (REFS 12, 28) . The lifetime prevalence of kidney stones in the United Kingdom increased by 63% (7.14-11.62%) between 2000 and 2010 (REF. 29 ).
The propensity to form stones varies according to sex, ethnicity and geography. Although historically stones have been 2-3times more common in men than in women, recent data indicate that this dis parity is diminishing. For example, data from the US Nationwide Inpatient Sample revealed a decline in the male to female ratio for hospital discharges for stones, from 1.7 in 1997 to 1.3 in 2002 (REF. 30 ). The male to female ratio of incident kidney stones also declined in Rochester, Minnesota, USA, from 3.1 to 1.3, between 1970 and 2000 (REF. 31 ). In Florida (USA), analysis of resource use related to procedures for stones revealed that the increase in rates in women was greater than that in men between 1998 and 2004 (REF. 32 ). In Canada, a 48% increase in stone treatment between 1991 and 2010 was primarily accounted for by an increase in procedures among women 33 . The reason for the surge in stone disease in women is not precisely understood, but some have speculated that it might be attributable to changes in lifestyle and diet, resulting in increased obesity among women, a known risk factor for stone formation 30 .
Racial and ethnic differences in stone prevalence have long been recognized. In the United States, non Hispanic white individuals have the highest prevalence among racial and ethnic groups (10.3%), followed by Hispanics (6.4%) and nonHispanic African Americans (4.3%) 12 .
Comparison of NHANES II (1988-1994) with NHANES III (2007) (2008) (2009) (2010) data has shown that the rise in kidney stone prevalence among Hispanics and African Americans was nearly double that of their white counterparts 12, 28 . Geographical variation in stone disease typically reflects environmental risk factors, with higher stone prevalence in hot, arid climates. In the United States, kid ney stones are most prevalent in the south and southeast regions and are lowest in the west of the country 28, [34] [35] [36] [37] . After controlling for other factors, ambient temper ature and sunlight have been shown to be independently associated with stone prevalence 35 . Numerous systemic diseases and factors have been associated with an increased risk of kidney stones. Weight, weight gain, body mass index 15, 38, 39 and dia betes 18, 40 have been shown in large prospective cohort studies to correlate with the risk of incident kidney stones, with a greater effect in women than in men in some cohorts. A multivariable model based on recent NHANES data showed that obesity and diabetes were associated with a 55% (95% CI: 1.25-1.94; P < 0.001) and a 59% (95 %CI: 1.22-2.07; P < 0.001) increased risk of kidney stones, respectively 12 . Metabolic syndrome has also been linked to risk of kidney stones, with NHANES data indicating that the number of metabolic traits corre lates with the risk of stones 41 . Jeong and colleagues 42 detected a 25% higher rate of radiographically detected kidney stones among individuals with metabolic syn drome in a screened population in Asia, after adjusting for confounding variables (95% CI: 1.03-1.50; P < 0.001).
Finally, risk of cardiovascular disease has been associ ated with a history of kidney stones, although a cause and effect relationship has not been definitively established. Ferraro and colleagues 43 showed a modest increased risk of incident cardiovascular disease among women with a history of stones (an adjusted multi variable hazard ratio of 1.30; 95% CI: 1.04-1.62) but not in men in three large prospective cohorts. Similarly, among individuals regis tered in the Canadian health care system, a 63% higher risk of incident myocardial infarction was detected among stone formers (95% CI: 1.51-1.76), with a greater effect in women than in men 44 . A matched pair analysis, adjusted for confounding factors, revealed a 31% higher risk of myocardial infarction in stone formers than in the general population in Olmstead County, Minnesota, USA (95% CI: 1.02-1.69) 45 .
Mechanisms/pathophysiology
Data from patients with stone disease provide visual and histological observations of the kidneys, microscopic and biochemical analyses of the urine and determination of the crystalline nature of the stones. Such observational data only produce a 'snapshot' at the end of a long pro cess of the stone formation. To understand the mech anistic details theoretical, animal and cell culture models have been developed. Indeed, results obtained from such studies are providing a better understanding of the pathogenesis of stone formation and are described here.
Microstructure of kidney stones
Kidney stones are solid masses, ranging in size from a grain of sand to a pearl (or larger) -a stone does not have to cause symptoms. Depending on their composition, stones are either yellow or brown in colour and smooth or jagged in appearance. They are composed of crystals (FIG. 2) and a ubiquitous organic matrix (FIG. 3) , which not only coats the crystals but is also present inside the crystals and the intercrystalline spaces [46] [47] [48] . The matrix of calcific stones contains many macromolecules, including osteo pontin (which also has a role in the biomineralization of bone), interαinhibitor (which is a plasma protein) and urinary prothrombin fragment 1 (UPTF1) -all of which are normally present in the urine 49 , albeit in small quantities [49] [50] [51] . The matrix also contains various forms of lipids, which have been shown to induce crystal nucle ation [52] [53] [54] [55] [56] . The association between the crystals and the matrix seems to start early upon crystal nucleation and continues throughout the formative and growth phases of the developing stone. Although some urinary molecules, such as UPTF1, are considered crystallization inhibitors, others such as osteopontin can act as both inhibitors and promoters of crystallization 57 . These molecules seem to be produced as a protective response against mineral ization. However, both CaOx and CaP crystals have been shown to induce the production of macromolecules that inhibit and/or modulate crystallization 51, [58] [59] [60] .
Calculi types. The four main types of stones are named after their major constituents. Calcium stones are the most common and occur as CaOx and CaP crystals, alone or in combination. Most kidney stones are par tially or completely composed of CaOx, which exists as a monohydrate or dihydrate. Individual crystals of CaOx monohydrate (COM) are thin and platelike, and generally acquire a 'dumbbell' shape through twinning, as seen in urinary sediments. Inside the stones, COM crystals are arranged radially into fanshaped profiles with distinct concentric laminations, showing out ward growth of the crystals and stones. CaOx dihydrate (COD) crystals have character istic tetragonal bipyrami dal shape both in urinary sediment and in kidney stones. CaOx stones are small with shiny exteriors and generally contain both COM and COD crystals. COM stones are more common than the pure COD stones 61 . In mixed stones, COD crystals are predominantly present on the stone surface, which appears jagged. By contrast, pure COM stones have smooth surfaces. CaOx stone forma tion is a multistep process (see below). Hypercalciuria, hyperoxaluria and hypocitraturia are major risk factors.
CaP is mainly found as basic CaP (apatite), calcium hydrogen phosphate dihydrate (brushite) or tricalcium phosphate (whitlockite). Pure CaP stones are rare 62 . Apatite is the most common crystal in kidney stones and is often a powdery mass that fills the spaces in between other types of crystals, mainly CaOx crystals. Whitlokite is very rare in both kidney stones and uri nary sediments. Brushite frequently occurs in kidney stones and is present as rosettes of radially arranged Figure 1 | Macroscopic and microscopic morphology of human kidneys and location of stones. a | According to the fixed-particle mechanism, stones begin as depositions of calcium phosphate (CaP) in the interstitium (apatite), grow outwards reaching the renal papillary surface, become exposed to the pelvic urine and establish a nucleus for the deposition of calcium oxalate (CaOx), leading to the formation of CaOx stones attached to a CaP base, known as Randall's plaques. b | By contrast, in the free-particle mechanism, for example, CaP, uric acid or cystine crystals form in the renal tubules, move with the urine, aggregate and plug the terminal collecting ducts. These plugs, called Randall's plugs or lesions, are exposed to the pelvic urine. Deposition of CaOx crystals on the CaP plugs leads to the formation of CaOx kidney stones.
thin bladelike crystals. Hypercalciuria, hypocitraturia and increased urinary pH are major risk factors for CaP stone formation 63 . Uric acid stones comprise 8-10% of all kidney stones worldwide, with a disproportionate prevalence in stone formers who are obese and insulin resistant -two of the main components of metabolic syndrome. Unlike calcium stone types, overly acidic urine (a pH of <5.5) is recog nized as the main abnormality responsible for uric acid nephrolithiasis 64 . In addition to the insolubility of uric acid at low urinary pH and dehydration, conditions that lead to excessive urinary uric acid excretion, known as hyperuricosuria, have also been associated with uric acid stone formation. These high levels might be due to excess dietary intake of purinerich foods 65 or endo genous uric acid overproduction, as occurs in conditions such as gout (gouty diathesis). Increased purine catabo lism (which can occur in those with myeloproliferative disorders or in those receiving chemotherapy) and the use of drugs that prevent renal reabsorption of uric acid are also contributing factors. Most uric acid stones are com pact, appearing like pebbles, with a central core of loosely aggregated anhydrous uric acid crystals surrounded by radiating columnar anhydrous uric acid crystals organ ized in concentric laminations 66, 67 . Some stones display a compact outer layer enclosing a porous friable interior consisting of anhydrous uric acid, uric acid dihydrate and COM crystals mixed with organic material.
Struvite stones, also known as 'infection stones' , rep resent 7-8% of all stones worldwide and are typically caused by increased production of ammonia secondary to infection with ureaseproducing organisms, such as Proteus or Klebsiella. The subsequent alkaline urine leads to the formation of magnesium ammonium phosphate hexa hydrate crystals 68 . Struvite and associated carbo nate apatite crystals can grow quickly into large stones referred to as staghorn calculi, appropriately named for their hornlike projections that occupy the renal pelvis and renal calyces. Although historically feared for their association with high mortality, struvite stones and their association with urosepsis and infections are now treatable with surgical intervention and antibiotics. In the modern era, these stone types are better known for their preponderance for recurrence, particularly in immuno compromised individuals with incomplete stone removal. Struvite stones are large aggregates of ortho rhombic 'coffinlid'shaped struvite crystals covered with spherulitic carbonate apatite crystals and mixed with cellular debris, which often included bacteria 67 . Finally, cystine stones form as result of an autosomal recessive defect in the renal transporter of the amino acid cystine 69 . The lack of cystine reabsorption leads to increased urinary cystine excretion. At normal urinary pH, cystine is insoluble and forms cystine crystals that can aggregate to form recurrent kidney and bladder stones. Cystine stones are compact, amber coloured, slightly opaque and with homogenous interiors. Higher magnification of the stone and urinary deposits reveals a unique and characteristic hexagonal structure of the cystine crystals 62 .
Chemistry of stone formation
Several models of kidney stone formation have been proposed; the two dominating mechanisms for the initi ation of stones are commonly described by the terms 'free particle' (in which crystals form 'Randall's plugs' in the tubule) and 'fixed particle' (in which stones grow on socalled Randall's plaques; FIG. 1) . Although these models encompass all the possible hypothetical models of how stones begin, no single model can rationalize the evidence observed from all patients with stones -many factors probably contribute. Regardless of the model, the chemical processes of nucleation and crystal growth are essential for the initiation and development of all stone types 70 . Stone formation is caused by an abnor mal combination of factors that influence the thermo dynamic driving force (supersaturation) and the kinetic (ratecontrolling) processes involved in the crystalliza tion of the various stoneforming minerals. The princi pal thermo dynamic driving force for both stages is the degree of supersaturation of the fluid within which initi ation occurs 70, 71 . Whether this takes place intracellularly or extracellularly, the laws of crystallization chemistry must apply.
Crystal nucleation. Nucleation (in which solute mol ecules dispersed in a solvent begin to cluster) is the first stage in crystallization and can occur homogeneously or heterogeneously. Homogeneous nucleation requires a high degree of supersaturation with respect to the min eral concerned; in vitro this would normally take place in a pure solution containing no particulate matter and in a receptacle that is chemically inert. By contrast, hetero geneous nucleation is the much more likely mechanism through which crystal initiation occurs in the urine 71 . The process can occur in the presence of particulates consisting of proteins, other organic polymers or crystals of another mineral, and is contained within receptacles lined with chemically active cell surfaces. Heterogeneous nucleation requires a lower level of supersaturation than homogeneous nucleation for crystal initiation.
Supersaturation. Estimating the degree of supersatur ation of urine with respect to each stoneforming mineral requires the measurement of 15 urinary constit uents, including any crystals that may have precipitated before or after micturition (urination) 2, [70] [71] [72] [73] [74] [75] . Using an iterative ion speciation programme 2, [72] [73] [74] [75] , these data can be used to calculate the concentrations of the various soluble complexes formed between these urinary con stituents, the ionic strength of the urine and the activity co efficients of all the ions involved. From this informa tion, the relative supersaturation (RSS) of the urine with respect to the mineral concerned can be calculated 73 ; this is the theoretical RSS that would be achieved if all potential crystalline material in the urine remained in solution.
The RSS level at which nucleation occurs is known as the formation product of the mineral concerned; it is not a fixed thermodynamic constant, but covers a range of supersaturation values within which de novo crystal nucleation can take place. Its value depends on several factors. First, the length of time of incubation affects the RSS. The longer a given supersaturated solu tion is left to stand, the more likely it is to precipitate crystals. The higher the initial RSS, the shorter is the nucle ation time 76 . Low initial levels of RSS generally require longer incubation times before nucleation takes place, which is important when considering the likeli hood of crystal nucleation occurring during the short period when urine is forming in the kidneys 77, 78 . The second factor that can affect the RSS value is the pos sible presence of nucleation inhibitors in the urine that could retard the process by 'poisoning' active growth sites on nascent crystals. Most studies on the effect of calcium salt nucleation inhibitors have been carried out using relatively long incubation periods (24-72 hours) and low RSS levels 79, 80 that do not mirror the situation in the kidneys. However, many of these presumed inhibitors have been shown to have little effect on the nucleation of calcium salts under conditions that mimic urine crystallization (that is, high RSS levels and short incubation (3-4 minutes)). Furthermore, the RSS of tubular fluid with respect to calcium salts often exceeds their 3-4minute formation product values 78, 81 . Thus, the concept that inhibitors of nucleation play a part in preventing calcium containing stones is question able because their effect may be overwhelmed by high ambient levels of supersaturation.
Crystal growth and agglomeration. Once a crystal nucleus is established inside the kidneys 71 , exposure to the urine enables the stone to grow by encrust ation 82, 83 . There are two basic pathways (freeparticle and fixedparticle mechanisms) for the establishment of a stone nucleus, both of which can be active in any stone former, although stones from idiopathic stone formers are generally formed attached to plaques 84, 85 ( FIG. 1) .
In the freeparticle mechanism 71, 77 , crystals nucle ate, grow and aggregate within the urine of the renal tubules. Once crystals aggregate to form large particles, they are retained inside the kidneys either by becoming too large to pass through the tubular lumens or by attaching themselves to the tubular epithelium 86 . In the presence of high supersaturation, crystal deposits occlude the collecting ducts 87 forming Randall's type 2 lesions or plugs 88 , which protrude out into the renal pelvis and become exposed to the pelvic urine. Once tubular openings are blocked, stasis can promote the formation of small stones behind the plugs. Similarly, unattached stones in the renal calyces can also form through the freeparticle mechanism.
Support for the freeparticle mechanism comes from animal models and tissue culture studies. Experimentally induced hyperoxaluria or hyper calciuria leads to increased urinary supersaturation and the formation of CaOx or CaP crystals in the renal tubular lumen 1, 89, 90 . Crystals are retained at sites where urin ary flow is impeded, either through a narrowing of the tubule as occurs where the proximal tubule meets the loop of Henle or at the papillary base where renal tubules bend 91 . Interestingly, the openings of the collect ing ducts are slitlike and narrower than the luminal diameter of the duct, which hinders urinary passage and might play a part in ductal plugging 77, 86 . Crystal retention is also accomplished by attaching to the renal epithelium, as well as the basement membrane, which has become exposed by epithelial sloughing 1, 92 . This mechanism is probably involved in the forma tion of apatite, brushite and cystine stones, as well as CaOx stones associated with primary hyperoxaluria and hyperoxaluria after bariatric surgery [93] [94] [95] [96] [97] [98] . Epithelial injury and sloughing is common in patients with brush ite stones and in hyperoxaluric CaOx stone formers 96, 99 . The plugs act as substrates for future crystal deposition and stone growth and can have the same or different crystalline composition 96, 97 . The alternative mechanism for stone development is the fixedparticle mechanism in which stones form attached to calcific plaques on the papillary surface. The plaques, called Randall's plaques, start with CaP crystal formation and deposition in the renal interstitium 88, 100 . A substantial number of idiopathic CaOx stones are formed attached to Randall's plaques 87, 101, 102 . The CaP deposits comprising the plaque seem to start deep in the renal interstitium, in the basement membrane of the loop of Henle 103, 104 , or are associated with the collecting ducts and vasa recta (the blood vessels that lie parallel to the loop of Henle) 105, 106 . Haggitt and Pitcock 107 exam ined kidneys from 100 randomly selected cadavers and performed light microscopy and transmission electron microscopy (TEM) on selected specimens. They found alizarin redpositive (which stains for cal cium) laminated spherulitic crystals in the interstitium, which, on closer examination by TEM, were shown to be associ ated with collagen fibres in the interstitium as well as the basement membrane of the collecting ducts. Furthermore, Cooke and colleagues 103,108 studied 62 normal kidneys and found calcification in four, all of which occurred in the basement membrane of the loop of Henle and extended into the medullary inter stitium. Some collecting ducts and blood vessels were also involved.
Highresolution radiography of cadaveric kidneys was performed by Stoller et al. 105 . They reported that 57% of the kidneys had subepithelial Randall's plaques that extended deep within the papillae and were inti mately associated with the collecting ducts and the vasa recta. Furthermore, von Kossapositive (which stains for CaP) spherical CaP deposits were identified scattered in the interstitium as well as around the collecting ducts and blood vessels. Evan et al. 96 examined renal papillae from patients with various causes who form stones. They concluded that all idiopathic calcium stones develop attached to subepithelial Randall's plaques 109 , and con firmed the earlier observations of Cooke et al. 103 96, 114 further hypothesized that deposits migrate from the basement membrane of the loop of Henle into the surrounding interstitium and become associated with type 1 collagen, fusing into a sync tium in which islands of mineral 'float' in an organic 'sea' . Microscopic and analytical studies of plaques have shown that interstitial CaP deposition occurs in close association with cellular degradation products, membrane bound vesicles, some unidentified fibril lary mat erial and collagen fibres 100 (FIG. 4) . Some vesicles contained needleshaped crystals, presumably CaP 100 . Accordingly, crystal formation has been proposed to begin in membranebound vesicles, propagated through the mineralization of collagen, leading to the move ment of a mineralization 'front' to the subepithelium of the renal papillae and the development of Randall's plaques 100 . Thus, there are differences of opinions about the beginning of the Randall's plaque. Does it start in the basement membrane of the loop of Henle, the vasa recta or the collecting ducts, or simply in the interstitium from where it grows outwards and in the process involves all components of the renal papillae? What provokes the formation of Randall's plaques is unknown. It has been proposed that the formation of Randall's plaques might be similar to vascular calcification 115, 116 (see below). One of the key differences between the free particle and fixedparticle mechanisms is the location of the initial nidus (FIG. 1 ). Randall's plugs (free particle) are tubular deposits -usually consisting of CaP -that are con tinuously exposed to the urine and grow accordingly. Conversely, Randall's plaques (fixed particle) are sub epithelial deposits that must have their surfaces breached before the crystalline mass is exposed to the urine for further growth (FIG. 5) . Such a breach can happen with the involvement of matrix metalloproteinases and/or owing to the sheer force of the growing plaque 88, 117 . Biological apa tite is the main constituent of the plaques, whereas plugs can be made of any solid that can precipitate out into the supersaturated urine. However, both plugs and plaques are coated with an organic matrix, which (as mentioned earlier) is made of macromolecules produced by renal epithelial cells in response to their exposure to tubular deposition of crystals. Pelvic urine is normally metastable with respect to CaOx and would support heterogeneous nucleation and growth of CaOx. Animal model and tissue culture studies have shown that continuous exposure of epithelial cells to crystals leads to the production of large amounts of macromolecules. These molecules travel down with the urine and, when coating the crystal aggre gates, promote further crystallization and stone growth. The formation and growth of CaOx crystals over plaques or plugs would eventually lead to the development of a calcific stone that is attached to the renal papillary tip. CaP by itself is also a good nucleator of CaOx 118 and has been shown to transform itself into CaOx through dissolution and recrystallization [119] [120] [121] . Thus, stone formation is the end product of a cascade of events (FIG. 6) .
Rate of crystal growth. The rate of crystal growth of a par ticular mineral is mainly dependent on its RSS level in the urine but might also be influenced by certain modifiers of crystallization. Some modifiers have been shown to retard the rate of growth and/or agglomeration of crystals of calcium salts in vitro. These modifiers include mag nesium 122 , citrate 123 , pyrophosphate 79, 80 , ADP 124 , ATP 124 , phosphopeptides 125 , various glycosaminoglycans 126, 127 , nonpolymerized Tamm-Horsfall protein (also known as uromodulin) 128, 129 , nephrocalcin 130, 131 , osteopontin 132, 133 , calgranulin 134 , α1 microglobulin 135 , β2microglobulin 136 , UPFT1 (REFS 137, 138) and interαinhibitor (bikunin light chain) 111, 139 . However, only citrate and magnesium have been found to be excreted in lower amounts by some calcium stone formers than by nonstone formers 140 . A second group of modifiers is postulated to stimu late the crystallization of calcium salts. Known as crystal lization promoters, they include matrix substance A 135 , various uncharacterized urinary proteins and glyco proteins [141] [142] [143] and the polymerized form of TammHorsfall protein (uromucoid) [144] [145] [146] . So far, stone formers have not been shown to excrete an excess of any of these macromolecules, but some researchers still believe that they might have a role in the growth phase of many stones and research continues on their possible role in promoting the development of stones.
Stone formation and vascular calcification
Several analyses have suggested a link between vascu lar calcification and the formation of idiopathic kidney stones [147] [148] [149] [150] [151] . Deposition of CaP in association with col lagen is similar to what is seen at sites of vascular calcifi cation, which is currently considered to be an active process in which vascular smooth muscle cells acquire an osteogenic phenotype [152] [153] [154] . Exposure of vascular smooth muscle cells to high levels of calcium and phos phate triggers this transformation 154, 155 , which activates bone morphogenetic proteins (BMPs) and WNT signal ling pathways via upregulation of Runtrelated transcrip tion factor 2 (RUNX2) and msh homeobox 2 (MSX2) transfection factors 156 . Transformation is also mediated by reactive oxygen species 157, 158 ; the transformed cells produce matrix proteins 154, 159 . Some evidence supports the theory that renal epithelial cells have the capacity to become osteogenic 116 . Basal levels of BMP2, RUNX2 and osterix (also known as Sp7; another transcription factor) are higher in genetic hypercalciuric rats that pro duce intrarenal CaP deposits 160 . Indeed, Madin-Darby canine kidney cells produce CaP microliths on the basal side when grown in monolayers 161, 162 , and exposure of these cells to high oxalate levels, as well as CaOx and CaP crystals, leads to the activation of NADPH oxidase and the production of reactive oxygen species 60, [163] [164] [165] [166] [167] , resulting in an osteogenic phenotype. Evidence has shown that genes considered to be involved in epithe lial transformation and bone morphogenesis -includ ing those that encode RUNX2, osterix, BMP2, BMP7, BMP receptor type 2, collagen, osteocalcin, osteo nectin, osteopontin, matrixglaprotein, osteoprotegrin, cadherin, fibronectin and vimentin -are upregulated in hyperoxaluric rats 168 , all of which are markers of the osteogenic phenotype. Overall, some evidence supports that the abnormal urinary conditions of hyperoxaluria, hypercalciuria, hypocitraturia and renal oxidative stress trigger the transformation of renal epithelial cells into osteoblastic phenotypes. The dedifferentiation pro motes the deposition of CaP crystals and the formation of Randall's plaques 88 .
Diagnosis, screening and prevention Patients with urinary stones generally present with the typical renoureteral colic and less frequently with loin pain; associated manifestations could be gross haema turia, vomiting and sometimes fever. However, patients can also be asymptomatic. A diagnosis of nephrolithiasis is only confirmed when a stone has been passed, has been extracted or destroyed, or has been identified in the urinary tract by imaging studies or surgery. Otherwise, other possible causes of the above manifestations should be investigated.
Symptoms of nephrolithiasis in children are often unclear. The only manifestations are microhaematuria or recurrent episodes of macrohaematuria; pollachiuriadysuria; acute or subacute episodes of recurrent abdom inal pain, located in the flank in older patients or diffuse in the abdomen in younger (<8 years of age) patients; urinary tract infections; or, finally, nonspecific manifest ations such as irritability, vomiting, unmotivated crying and motor agitation in those <2 years of age. In the absence of a clear demonstration of a stone, the only clue that these manifestations are due to urinary stones could be the observation of concurrent hypercalciuria or hyperuricosuria.
A detailed medical history and physical examination is part of the evaluation of patients with a suspected stone. Clinical diagnosis generally needs to be supported by appropriate imaging. Renal and urinary tract ultrasono graphy can identify stones that are situated in the calices, the pelvis and the pyeloureteric and vesico ureteric junc tions; it may also identify indirect signs of a stone such as pyeloureteric dilation and a perirenal film of extrava sated urine. Indeed, ultrasonography has been shown to identify renal stones with a sensitivity of 70% and a specificity of 94% 169 . For ureteral stones, the sensitivity and specificity of ultrasonography is lower at 57.3% and 97.5%, respectively 170 . Plain abdominal Xray imaging is generally not used anymore in the evaluation of a flank pain given its modest diagnostic performance (sensitivity and specificity of 44-77% and 80-87%, respectively) 171 . However, plain abdominal Xray imaging might still have a role in distinguishing between radiopaque and radiolucent stones and in followup care 172 . Intravenous urography, which was the historical goldstandard imaging technique for urolithiasis, has been replaced by noncontrastenhanced CT (NCCT) owing to its higher sensitivity and specificity for identify ing ure teral stones regardless of location, size and composition; its lack of contrast agents; and because it can recognize extraurinary causes of renal colic in 30% of patients 173 . Moreover, NCCT can determine the stone density and inner structure, as well as the skintostone distance, which are useful ahead of extracorporeal SWL 174 .
Categories of stone formers
Patients with kidney stones are generally classified in different categories according to the composition of stones and the history of previous stone episodes. This classification influences the diagnostic work up and preventive treatment. However, both of these aspects have limitations. For example, classification according to stone composition has the caveat that chemical meth ods are imprecise and do not distinguish the crystalline forms 175 ; infrared spectroscopy or Xray diffraction are the preferred methods.
Classification according to a history of previous stone episodes is easier because a single stone former is defined as one who seeks advice for a single kidney stone episode; by contrast, a recurrent stone former is a (FIG. 1) . Alternatively, crystal formation occurs in the renal tubules (step 3). CaP crystals translocate into the interstitium (step 4) or are internalized by the cells, dissolved and re-precipitated in the tubular basement membrane 121 . Another possibility is that renal epithelial cells, when exposed to CaP and/or CaOx, produce reactive oxygen species and, probably, a range of factors associated with osteogenesis, such as Runt-related transcription factor 2 (RUNX2), osterix (also known as Sp7), bone morphogenetic protein 2 (BMP2), BMP7, BMP receptor type 2 (BMPR2), collagen and osteopontin. Epithelial cells produce matrix vesicles on the basal side (step 5) followed by their calcification (step 6; REFS 88, 168) . b | Once CaP crystals have been deposited in the basement membrane of the loop of Henle and/or collecting ducts, mineralization continues. Collagen fibres and membranous vesicles become calcified (step 1). The mineralization front reaches the renal papillary surface and a subepithelial plaque is established (step 2). The papillary surface epithelium is disrupted (step 3) and plaques rupture, exposing the CaP crystals to the pelvic urine metastable with respect to CaOx (step 4). Urinary macromolecules are deposited over the exposed CaP crystals, promoting the deposition of CaOx crystals on the CaP base (step 5).
patient who has passed many temporally spaced stones. Given that no metabolic markers are available to distin guish between single and recurrent stone formers, a long observation period is required to determine whether a patient is a single or a recurrent stone former. The majority of stone formers will pass only a single stone in their lifetime or over a long observation period 176 . Furthermore, recurrence of stone formation in most firsttime calcium stone formers occurs in a period that could be as long as 5 years, and only 15-20% of calcium stone formers recur ≥4 times 176 . Accordingly, the term recurrent calcium stone former has been proposed to describe a patient who has experienced three or more episodes of passing stones in a 5year period 176 . Other patients with some stone recurrence can be identified as occasionally recurrent or sporadic stone formers.
Although the number of stones formed by a patient denotes the clinical activity of the stone disease, the con cept of metabolic activity of the stone disease is different. Metabolic activity in stone disease refers to an ongoing crystallizationdriving process that will probably lead to new stones or to the growth of the existing stones. It is this concept that should ideally drive the clinician's deci sion on how to treat the patient. Unfortunately, we do not have reliable metabolic markers. Patients with their first (and most likely only) stone might have the same metabolic urine abnormalities observed in those with recurrent stones 177 ; the same is probably the case for the occasional recurrent stone former. Thus, we must rely on a surrogate marker of metabolic activity: clinical activity, which has limitations. A recurrent calcium stone former, who has passed many new stones in a relatively short period of time, should be considered as metabolically active, as should a patient who exhibits stone growth on serial imaging even if it is their first stone. By contrast, a patient with multiple kidney stones discovered on the same occasion could not be clinically active because the cluster of stones could have formed previously in a short timeframe as a result of timeconcentrated, non longlasting and unique metabolic derangements. Thus, when the stones formed, the patient was metabolically active but might not be at the moment of diagnosis.
We suggest that stone disease should not be evaluated only in reference to stone composition and clinical activ ity, but the risk of complications should also be appraised in the diagnostic process and patient categorization
.
Diagnosis
Diagnosing and developing effective prevention strat egies requires both understanding the metabolic back ground that promotes lithogenesis and assessing the patient's risk of CKD and metabolic bone disease (MBD). Metabolic evaluation of patients with stones aims to esti mate the propensity of the urine to crystallize, investigate the metabolic mechanisms of nephrolithiasis, diagnose underlying systemic causes of nephrolithiasis, determine the risk of CKD and MBD and to achieve insights on nutritional habits.
Specific software for estimating the urine propensity for crystallization have been proposed (for example, the EQUIL and JESS programs) 73, 178 . These programs cal culate the urinary supersaturation of numerous salts by considering the concentration in the urine of different ionic species. The probability of stone formation can also be evaluated by algorithms based on urine excretion of a limited number of parameters 140 . Although these methods can be of help, they are not compulsory for a successful metabolic assessment and followup.
Risk factors of CKD and MBD. The categorization of firsttime or sporadic stone formers, according to CKD or MBD risk, aims to identify those who require pharmacological prevention and/or special attention during followup care. Risk factors for MBD in stone formers include distal renal tubular acidosis (complete or incomplete), medullary sponge kidney, primary hyperparathyroidism, malabsorptive syndromes, fast ing hypercalciuria and genetic disorders (for example, sodiumphosphate transporter disorders) 179 . In calcium stone formers, the risk of developing CKD is increased as a result of systemic or renal tubular disorders, high recurrence rates or in those with MBD. All patients with noncalcium nephrolithiasis are at risk of develop ing CKD and recurrent stones. In firsttime or sporadic stone formers, stone composition, family and personal recall, imaging and laboratory data would suggest that these individuals have disorders that put them at a higher risk of CKD
. Children (and young adults) should be considered at high risk of developing CKD and MBD 180 . CKD can also result from whatever has caused stones to precipitate, renal damage from stone complications (pyelonephritis and obstructive nephropathy) or can be the result of urological treatment 181 . Referral to a neph rologist is highly recommended in patients with stones and CKD.
Stone analysis. Knowledge of stone composition is fundamental in noncalcium stone formers; in these cases, it is a formidable pathway to diagnosis. For instance, finding that a stone is pure cystine or con tains even a small percentage of cystine is diagnostic of cystinuria (an inherited autosomal recessive disease). Furthermore, discovering a composite stone of struvite and CaOx is a strong hint of the existence of a meta bolic disorder 182 . In calcium stones, the precise recog nition of the mineral components is much less relevant. The identification of apatite as a major component of a stone could suggest renal tubular acidosis or primary hyperparathyroidism, but this is not always the case. Finding brushite, another crystalline form of CaP, sug gests moreactive stone disease that is less amenable to preventive treatments and increases the risk of CKD 183 . Most calcium stones have mixed composition; this is believed to depend on the pathogenetic mechanisms involved in lithogenesis (that is, low levels of apatite in a CaOx stone suggests lithogenesis on Randall's plaques) and/or on the superimposition of a different form of lithogenesis (for example, a mixed CaOx and uric acid stone). The calcium composition of a stone can be deduced by the plain abdominal Xray imaging of radiopaque stones. Dualenergy CT shows promise as a diagnostic tool for uric acid stones 184 .
Laboratory evaluations.
In all stone formers, the initial metabolic work up is best performed ≥3 weeks after the acute episode, such as renal colic with or without stone passage, obstruction, stone removal or concomi tant urinary tract infection. In calcium stone formers, the diagnostic algorithm differs according to the his tory of previous stones and/or comorbidities (TABLE 1) . Conversely, the diagnostic algorithm for individuals with noncalcium stones (TABLE 2) is dependent on stone composition only because many of these con ditions are recurrent and/or have a high risk of CKD and ESRD. If the stone is not analysed or its composi tion is unknown, the patient should be investigated as a calcium stone former (TABLE 1) . Children who have passed stones with calcium or of unknown composi tion should be evaluated intensively as recurrent stone formers. However, in these patients, 24hour urine col lection and MBDrelated evaluations could be difficult to undertake; thus, analyses of the spot urine might be sufficient.
Genetic investigations.
A recent study has concluded that in up to 11.4% of adult and 20.8% of paediatric patients with renal stones and nephrocalcinosis, pre viously unsuspected monogenic disorders such as cystinuria were eventually diagnosed 185 . This finding is at odds with several investigations that did not find carriers of mutated genes in large series of patients with renal stones and/or hypercalciuria 186 . Accordingly, a systematic investigation of patients with stones for genetic mutations is probably not warranted. Instead, these findings implicitly suggest that patients should be thoroughly investigated for the clinical manifestations of inherited disorders 180 .
Prevention
Stone formation can be a recurring disease that may have severe consequences, such as CKD, MBD and ESRD. Thus, the aim of preventive strategies should also focus on CKD, MBD and ESRD. Examples that such an approach is possible, at least with respect to MBD, have been reported 187, 188 . Comprehensive meta bolic evaluation is followed by a range of preventive measures, including specific pharmacological interven tions in addition to advice for a change in lifestyle and nutritional habits.
Recurrent calcium stones. Although prevention of new calcium stones is possible, there is no pharmacological treatment that can dissolve existing calcium stones. In nonidiopathic calcium nephrolithiasis, the primary conditions should be addressed with specific treatments. In these cases, preventive measures are supportive. In the majority of patients with idiopathic stone disease, behavioural and nutritional interventions are poten tially helpful and should be the first step of stone pre vention 189 . Nutritional advice for patients with calcium
Box 2 | Stones and risk of chronic kidney disease
The conditions reported in this box complicate more or less frequently with chronic kidney disease (CKD). The different categories of CKD risk are arbitrarily attributed by the author (G.G.) on the basis of personal experience and the literature. No or very few studies have investigated the prevalence or incidence of CKD in the listed conditions; for some of the rarest stones, the risk attribution was based on few case reports. stones include increased water intake (>2 l per day and >3 l per day in the summer) to provide 24hour diuresis of >2 l 190 , and maintenance of a balanced diet with cal cium intake not <800-1,000 mg per day, reduced meat and poultry intake (≤0.8 g per kg of body weight) 191 , reduced salt intake (<2 g per day, which is equivalent to 5 g of table salt (sodium chloride)), avoidance of excess food intake, increased vegetable consumption 192 and avoidance of soda beverages 193 . Low calcium diets should be avoided in the majority of patients because they increase intestinal absorption and urinary excretion of oxalate, thereby increasing lithogenesis 194 ; furthermore, such diets can cause or worsen MBD in calcium stone formers. Low oxalate diets are difficult to attain because of the presence of oxalate in many common foods. Only foods with very high oxalate content should be limited or avoided (see https://regepi.bwh.harvard.edu/health/Oxalate/files). The concomitant consumption of foods that are rich in oxalate and calcium is a possible strategy to decrease the absorption of oxalate 195 . Drug treatment could be considered if stones con tinue to recur despite the above measures, or if the CKD and/or MBD risks are considerable, or in cer tain groups of people (for example, flying airline per sonnel) and in those who have severe urine metabolic abnormal ities. For example, thiazides reduce calciuria and might improve bone mineral density 179 and should be considered in patients with high or relatively high urine calcium levels and recurrent calcium stones. However, thiazides have also been shown to decrease stone activity in individuals with normocalciuria 196 . Indeed, the American Urological Association guide lines 195 suggest that lowering calciuria with thiazides might be effective regardless of the absolute rate of calcium excretion. Thiazides are appropriate for both CaOx and CaP stones when dietary measures and increased fluid intake have not been successful in prevent ing stone recurrence. Allopurinol or febuxostat could be useful in patients with calcium stones who are hyperuricosuric 195 ; the former was shown to be effect ive in reducing urinary uric acid and stone recurrence in hyper uricosuric CaOx stone formers without other metabolic abnormalities 197 . Although no data support its use, the hypouricosuric effect of febuxostat suggests that this drug could be effective in stone formers who cannot tolerate allopurinol 198 . Citrate (generally potassium citrate) use to increase citraturia, which raises the inhibitory activity against cal cium crystallization 199 , has been shown to be effective in two randomized trials 200, 201 . Citrate is indicated in those with recurrent CaOx stones with decreased urinary cit rate excretion; in patients with complete or incomplete distal renal tubular acidosis, chronic diarrhoeal states, druginduced or dietinduced hypocitraturia; and in patients with MBD who form stones. In general, potas sium citrate is preferred to sodium citrate because it attenuates calciuria and, therefore, is likely to be more effective in preventing calcium stones 202 . However, some concern pertains to overtreatment with citrate, which in theory might increase the risk of forming new CaP stones because it raises urinary pH (via its metabolism to bicarbonate by the liver). However, in patients with medullary sponge kidney and/or distal renal tubular acidosis and preexisting high urinary pH, kidney stone recurrence rate is decreased rather than increased after treatment with citrate 203, 204 .
Possible risk of CKD
Uric acid stones. To prevent frequently occurring uric acid stones, uric acid supersaturation in the urine must be decreased. This can be achieved by increasing uri nary volume (>2 l per day), increasing urinary pH to approximately 7.0, decreasing uricosuria and admin istering sodium bicarbonate or potassium citrate. The determination of ion concentrations aims to recognize secondary forms of urolithiasis and risk of CKD and MBD. High calcium and/or low phosphate levels suggest hyperparathyroidism; low or marginally low potassium levels suggest renal tubular acidosis. Low bicarbonate levels suggest renal tubular acidosis. § Data from at least two 24-hour urine collections in the usual conditions of diet and fluid intake should be obtained. Collections should be performed in plastic bottles following laboratory instructions. The accuracy of the collection could be checked by evaluating creatininuria.
||
The urinary calcium to creatinine ratio in a morning (fasting) spot urine sample is performed in patients with hypercalciuria; it is a marker of the obligatory urinary loss of calcium. Values of >0.25 mg per mg suggest an increased bone turnover. ¶ The test is optional to confirm renal tubular acidosis, which should be suspected in patients with or without systemic acidosis and recurrent nephrolithiasis of pure calcium phosphate (CaP) stones or stones mainly composed of CaP. Renal tubular acidosis should also be considered in recurrent calcium stone formers (both calcium oxalate and CaP) with hypocitraturia and a urinary pH of >5.8 and in patients with nephrocalcinosis.
# Urinary hydroxyproline, or urinary or serum deoxypyridinoline crosslinks. Assessment can help to monitor the effects of treatment on MBD
280
. **The 24-hour urinary excretion of sodium, potassium, phosphate and urea provide important information on the nutritional habits of the patient, and the daily protein intake can be estimated. ‡ ‡ When blood tests suggest hyperparathyroidism, serum parathyroid hormone levels should be measured and parathyroid imaging should be performed. § § In patients with hypercalciuria.
Although not supported by data from clinical trials, allopurinol or febuxostat can be used if the patient has hyper uricosuria and dietary measures fail to normalize urinary uric acid 205 .
Cystine stones. Reducing the concentration of cystine in the urine and increasing its solubility will prevent stone formation in this highly recurrent stone dis ease. The preventive strategy involves increasing water intake to >3 l per day and the administration of sodium bicarbo nate or potassium citrate to raise urinary pH and increase the solubility of cystine. Early in the treatment course, urinary pH should be checked multiple times per day to titrate the quantity of alkali; at a later stage of treatment, the urinary pH should be monitored less fre quently. The target pH is 7.0-8.0 (REF. 195 ). If cystinuria is >300 μmol per mmol of creatinine (>2,600 μmol per g of creatinine) or if the aforementioned measures fail to prevent new stones, 6mercaptopropionyl glycine can be administered, with dpenicillamine as an alternative treatment 195 . Given that both drugs can cause protein uric glomerular diseases, urine should be periodically monitored for proteinuria. Ideally, cystine solubility should be assessed; numerous methods have been pro posed [206] [207] [208] , but few laboratories have this capacity. Thus, generally, treatment is guided by cystine stone formation and/or growth.
Patients with cystine stones require close followup because of the high metabolic activity of the disease (with a very high risk of stone recurrence, the rapid growth of these stones, staghorn stone formation, need of surgical procedures and CKD occurrence) and because of the possible adverse effects of treatment. Indeed, a French cohort study of 442 patients showed that 26.7% had CKD and only 22.5% had a (normal) estimated glomeru lar filtration rate (eGFR) of >90 ml/min/1.73 m 2 ; a his tory of staghorn stones and multiple open surgical stone procedures constituted a relevant risk factor for CKD and nephrectomy 209 . Accordingly, patients should be monitored for urinary pH and volume.
Struvite stones. The risk of recurrence of struvite stones is high. Particularly in men, these 'infection stones' are a complication of common calcium stones 182 ; thus, it is important to look for and treat the metabolic abnor malities that are typical of calcium nephrolithiasis in these patients. Complete removal of struvite stones is a prerequisite for successful recurrence prevention. Indeed, it is almost impossible to cure infection in the presence of the stone because it represents a micro organism reservoir. After clearing the stones, long term (several months) targeted antibiotic treatment might be necessary to keep urine sterile and prevent new stone formation 205 .
Management

Surgical management
Over the past 30 years, the management of paediatric and adult patients with symptomatic kidney stones has evolved from open surgical lithotomy to minimally invasive endourological approaches. The three most common treatment modalities for renal stones include extracorporeal SWL (40-50% worldwide use), rigid or flexible retrograde ureteroscopic stone fragment ation and retrieval (30-40%) and PCNL (5-10%). Each of these therapies has its own particular adverseeffect profile and expected success rate depending on the experi ence of the treating physician, stone factors (size, location and composition) and patient characteristics (body habitus, medical comorbidities and anatomy). With appropriate counselling and proper procedure selection, patients should expect high stone clearance rates, low associated morbidity and quick recovery times. A general decisiontree algorithm of the most common of these approaches, stratified by stone location, stone size and stone density, is presented in FIG. 7. Shockwave lithotripsy. SWL involves the noninvasive delivery of highenergy acoustic waves that fragment a kidney stone. The shockwave, created by electro hydraulic, electromagnetic or other types of energy eGFR, estimated glomerular filtration rate; N/A, not applicable. *Data from at least two 24-hour urine collections in the usual conditions of diet and fluid intake should be obtained. Collections should be performed in plastic bottles following laboratory instructions. The accuracy of the collection could be checked by evaluating creatinine levels in the urine. ‡ Given that struvite stones could be a complication of common calcium stones, especially in men, the common metabolic risk factors for calcium stones should be examined. § Typical crystals of the corresponding condition can be observed.
||
It has the same background conditions of infection stones. ¶ Total proteinuria has to be checked in patients who are treated or are going to be treated with 6-mercaptopropionyl glycine or d-penicillamine.
#
The determination of pH in spot urine during the day is useful for treatment guidance.
sources, travels through the patient and is focused on the stone using an acoustic lens. When these shock waves approach and pass through the calculus, energy is released resulting in internal structure disruption and stone fragmentation. Fluoroscopic or ultrasonographic guidance is routinely used during SWL to aid in calculus targeting and for precise acousticwave focusing. Deep sedation or general anaesthesia is commonly used for intra operative analgesia, as well as to control respir atory renal movement. Although recent Canadian and US medical claims data have demonstrated a marked decrease in use over the past decade, SWL remains the most commonly performed endourological kidney stone procedure worldwide 210, 211 . The success of SWL is typically determined 1-3 months after the procedure by plain abdominal Xray with or without renal ultrasonography. As small residual fragments of <4 mm in size within the kidney are considered to be passable, patients with these clin ically insignificant stones are often referred to as stone free by most classification systems 212 . This misnomer becomes confusing when comparing stonefree rates among studies using plain abdominal Xray versus CT imaging because CT is more sensitive than Xray or renal ultrasonography for assessing residual kidney stones. Despite these discrepancies, stonefree rates for SWL are considered equivalent to those of ureteroscopic retrieval (50-80% success) for small radiopaque stones (<2 cm in size) located in nondependent portions of the kidney (upper pole, middle pole or renal pelvis; TABLE 3). Stones located in the lower pole of the kidney remain the most daunting clinical challenge for endourologists perform ing SWL. Multiple explanations have been offered for the poor stonefree rates for lowerpole stones, including anatomical factors (long, narrow lowerpole infundibu lum) and the dependent position of the calculi limit ing the passage of fragments 213 . Owing to these factors and the poor stone passage rates for larger stones, most clinicians do not perform SWL for lowerpole stones that are >1 cm in size 214, 215 . In addition to lowerpole limitations, SWL might require repeated treatments to match the efficacies of PCNL and ureteroscopic retrieval 211, 216 . This retreat ment risk is associated with obesity (a body mass index of >30) and with extremely dense stones. Patients who are obese are believed to have lower SWL success rates because their kidneys -and, accordingly, stone depth -exceed the lithotripter focal length (shockwaves only penetrate 12-14 cm) and/or their body habitus prevents adequate stone visualization at the time of lithotripsy 217, 218 . Dense stones, such as cystine, brushite or COM, are more resistant to SWL fragmentation. As stone composition is usually unknown before surgery, CT stone attenuation values in Hounsfield units (HUs) are commonly used as preoperative surrogates for stone density. Although variable, most urologists use high attenuation values of >1,000 HU as a predictor of renal stone disintegration failure that should be considered before undertaking SWL 219 . Overall, most of the SWL shortcomings are sur mounted by the excellent qualityoflife (QOL) meas ures and low morbidity associated with the procedure. Patients who undergo SWL have repeatedly been shown to have faster return to work, shorter recovery times and higher satisfaction scores than those who undergo ureteroscopic retrieval, especially if SWL occurs with out stenting 215 . SWL also has a low complication pro file, including a 5% rate of steinstrasse (that is, stone fragment buildup within the ureter) and a 2% rate of urinary tract infection (TABLE 3) . Major complications such as sepsis or profound haemorrhage are rare but deserve mention. The development of sepsis following SWL is low in absolute terms (<1% of patients), but is considerably higher in the presence of staghorn or col onized stones (up to 10% of patients) 220 . To mitigate this risk, patients with urinary obstruction or positive urine cultures before SWL should be completely treated. The majority of patients who undergo SWL develop tran sient haematuria that resolves within days, and imaging studies in asymptomatic patients postprocedure have shown a haematoma rate of 25% 221 . However, sympto matic fluid collections (perirenal, subcapsular or intra renal haematomas) are rare (<1% of patients), and the rate of postSWL blood transfusions are very low (<0.2% of patients).
Ureteroscopic fragmentation and retrieval. Uretero scopy consists of retrograde passage of an endoscope from the urethra proximally towards the affected ure ter and kidney, enabling access to the stone as well as delivery of other instruments, such as guidewires, balloon dilators, laser fibres and baskets. Although fairly noninvasive, ureteroscopy requires spinal or general anaesthesia to minimize pain and the vis ceral response to ureteral and renal dilation. Rigid Nature Reviews | Disease Primers
Lower pole
Stone location
Stone size or morphology CT evaluation Treatment
Shockwave lithotripsy Ureteroscopic retrieval Percutaneous nephrolithotomy
Elective stone removal
Symptomatic kidney stone
Upper or middle pole <1 cm >1.5 cm <2 cm ≥2 cm or staghorn 1-1.5 cm High attenuation Low attenuation Figure 7 | Algorithm for the most common approaches to surgical treatment of kidney stones. The decision of which surgical strategy to use is dictated by the location of the stone (with lower-pole stones being more difficult to treat), stone size and stone density.
ureteroscopes are reserved for distal ureteral stones, whereas flexible uretero scopes, with their deflection ability, are used to reach the extremes of the renal collect ing system and negotiate access to anatomically difficult renal calyceal variants. Some urologists place ureteral access sheaths (long reinforced hollow tubes) from the urethra to the renal pelvis to enable repetitive passage of the ureteroscope while minimizing uro thelial trauma. These sheaths also enable the continuous flow of irrigation fluid, improving stone visualization and facilitating a lowpressure system. Although flexible electrohydraulic lithotripters are available, the holmium yttriumaluminium garnet (Ho:YAG) laser remains the preferred method of lithotripsy in most centres in devel oped countries owing to its rapid absorption in water and minimal tissue penetration 213 . A recent metaanalysis of seven large randomized controlled trials totalling >1,200 patients demonstrated that ureteroscopic retrieval achieved a higher ureteral and kidney stonefree rate and a lower need for retreatment than did SWL 222 . As such, for ureteral stones <10 mm in size, SWL and ureteroscopy are considered firstline therapy. For ureteral stones >10 mm in size, ureteroscopic fragmentation results in higher stonefree rates and fewer procedures 223 . For renal stones in non dependent loca tions such as the lower pole, uretero scopy stonefree rates are comparable to those of SWL, if not slightly better (TABLE 3) . Like SWL, uretero scopic manage ment of lower pole stones is frequently more challenging than for stones located elsewhere in the kidney. Not only can acute infundibular angles make deflection and manoeuvr ing of the scope difficult but also the passage of the accessory instruments through the ureteroscope working channel reduces the ability of the surgeon to actively deflect the ureteroscope, creating a scenario in which a lowerpole stone can be visualized but not manipulated 213 . With the advent of smaller flexible endoscopes and tipless stone baskets, many endo urologists relocate lowerpole stones into a morefavourable upperpole location before fragmentation 224 .
Compared with SWL, ureteroscopy is associated with higher procedurerelated complication rates and longer hospital stays (TABLE 3) . Many of the symptoms that raise complication rates are secondary to the ure teral stent that is left in place following the procedure 213 . These small, hollow polyurethane tubes are designed with proximal and distal coils to maintain their position within the kidney and the bladder. Unfortunately, the distal bladder coil can be felt by the majority of patients, causing haematuria and irritative voiding symptoms that range from mild to intolerable 215 . Ureteroscopy is favoured over SWL in the setting of multiple or radio lucent stones (stones that are not visible on plain film), hydronephrosis, obesity or highdensity stones (holmium lasers are able to fragment all stone types). Ureteroscopy for renal stones during pregnancy or in patients with bleeding diathesis is unusual but would be considered the safest approach, if necessary (TABLE 3) .
Percutaneous nephrolithotomy. PCNL involves the direct passage of an endoscope percutaneously through skin, muscle and perirenal fat, and into the kidney and is generally performed for stones >2 cm in size. With the patient under general anaesthesia in either the prone or supine position, the kidney is located using anatomical markings. Renal access is achieved under fluoroscopic and/or ultrasonographic guidance and can be combined with endoscopic or radiographic imaging techniques. For the posterior approach, renal access below the 12 th rib is preferred to avoid the pleural cavity and intercostal vessels and nerves. A needle puncture into a posterior calyx rather than the renal pelvis is also recommended to avoid posterior renal artery or vein branch injury. This 'access' can be performed preoperatively as an out patient procedure in an angiography suite (percutaneous nephrostomy tube placement) or preferably during the same setting as PCNL.
Worldwide, approximately 70% of all renal access for PCNL occurs in the lowerpole calyx, and prior cysto scopic placement of a ureteral catheter for retrograde injection of a contrast has been shown to dramatically improve targeting and access to the kidney 225 . Once entry into the kidney has been achieved, a guidewire is then advanced antegrade to the bladder to maintain access and enable passage of either sequential or balloon dilators to expand the tract. After dilation and placement of a working sheath, both rigid and flexible nephro scopes can be passed into the kidney for stone removal and lithotripsy. After the procedure, nephrostomy tubes with or without a ureteral catheter or a ureteral stent by itself ('tubeless' stents) are left in place to facilitate maximal renal drainage 226 . PCNL generally offers very high stonefree rates in the 80-90% range, which can be attributed to the shorter working distance, the introduction of relatively large working sheaths (30 French or 10 mm) and more effective instruments for the removal of larger stone fragments (TABLE 3) . For patients with a stone burden of >2 cm or staghorn calculi, PCNL is considered the standard of care, mirroring the successes of open surgery while decreasing the length of hospital stay by 75% 227 . PCNL is regarded as being more effective than uretero scopic procedures or SWL for most stones, but is more invasive. For ureteral stones, antegrade access to the ure ter can also be achieved with high success depending on the ureteral diameter. However, ureteral stone manage ment is typically reserved for lessinvasive approaches and smaller stones.
Owing to its moreinvasive nature, especially for larger and branched stones, PCNL has a greater compli cation profile than lessinvasive endoscopic techniques, including a 2% sepsis risk and a 5% risk of requiring blood transfusion 228 . Other complications are also reported with varying frequency, such as pneumothorax (1% of patients, usually with upperpole access), arterial injury requiring embolization (0.3% of patients) and colonic perforation (rare) 213 . As stone clearance relies on visibility, nuisance bleeding can obstruct visibil ity, requiring procedure termination, placement of a nephrostomy tube and a return operating room appoint ment at a later date. Anatomical limitations, such as narrow infundibulum or entrances at acute angles to the tract, can also make it difficult to access the entire caly ceal system through one tract. In these cases, a second or even third access tract is required to obtain complete stone clearance, occasionally even requiring a combined retrograde approach.
Medical management
Treatment of renal colic and medical expulsive therapy. Treatment of the pain associated with kidney stones (renal colic) is based on the use of NSAIDs as a first choice in the absence of contraindications 229, 230 and, in case of failure in relieving pain, opioids. Intravenous para cetamol (acetaminophen) also seems to be as effect ive as morphine 231 . The use of antispasmodics does not seem to have a significant effect 229, 232 . If analgesia cannot be achieved with the previous measures, drainage of the renal pelvis through percutaneous nephrostomy or ureteral stenting and eventually stone removal should be performed.
Hydration should be normal and intravenous fluids are only indicated in the case of protracted vomiting because it does not favour stone expulsion but instead increases pain and the risk of complications (renal pelvic rupture and urine extravasation) 233 . αAdrenergic recep tor antagonists (mainly tamsulosin) 234, 235 and calcium channel blockers 234 have been demonstrated to be an effective medical expulsive therapy, believed to be due to their ability to dilate the distal ureter and increase the probability of spontaneous stone passage. The efficacy of these agents in promoting the passage of small distal ureteral stones (<5 mm in size) has recently been decried by two welldesigned, randomized, placebocontrolled trials, one of which found efficacy only for larger stones (≥5 mm in size) and the other found no efficacy for stones of any size 236, 237 .
Oral and percutaneous dissolution therapy of stones.
Oral dissolution of existing stones is generally effective only with uric acid stones. Twothirds of these stones can be at least partially dissolved by following the same rules suggested for their prevention: modulating the pH of urine to 7.0, increasing urinary volume and decreas ing uricosuria with allopurinol or febuxostat 238, 239 . Few obser vations also suggest that cystine stones might be amen able to oral chemolysis with 6 mercaptopropionyl glycine, high urine output and alkalinization 240 . Finally, the use of percutaneous solutions, such as 10% hemi acidrin or Suby's solution, to turn insoluble kidney stones into morewatersoluble forms was popularized in the 1960s but is rarely used today. Although some what effective for infection, uric acid, cystine and brush ite stones, percutaneous dissolution of kidney stones is labour intensive and considerably less effective than contemporary minimally invasive removal techniques 241 .
Quality of life
As indicated earlier, the prevalence of urolithiasis and nephrolithiasis has increased over the past decades and affects approximately 9% of the American adult popula tion 12 . Although many kidney stones remain asympto matic for long periods, the incidence of stone episodes, such as pain, infection or obstruction, has increased 27 . Furthermore, following an initial stone event, >50% of patients experience a recurrent stone in the follow ing 5 years 242 . Thus, for these patients, treatment (both medical and surgical) and implementation of lifestyle modifications can significantly affect patient QOL.
The most commonly used QOL questionnaire in the literature is the 36Item ShortForm Health Survey (SF36) questionnaire, which consists of selfadministered ques tions (a total of 36) divided into eight domains including: physical function, role limitations due to physical health problems, bodily pain, general health perception, vitality, social function, role limitations due to emotional problems and mental health 243 . The eight domains are scored from 0 (worst) to 100 (optimal). Three US studies using this questionnaire compared stone formers to healthy adults and found lower scores in stone formers in two (general health perception and bodily pain), five (physical function, role limitations due to physical health problems, general health perception, social function and role limit ations due to emotional problems) and six (all except role limitations due to emotional problems and mental health) of the eight domains, respectively [244] [245] [246] . Among stone formers, one study reported that cystine stone formers had the worst QOL owing to role limitations caused by emotional problems 247 . When comparing scores between men and women, most of the studies reported lower QOL in female stone formers [244] [245] [246] [247] . However, these results have to be inter preted with caution because the timing of the question naire in relation to the last stone event has a signifi cant effect on the SF36 score. When adjusting results accord ing to the interval from the last stone episode, patients with a recent stone event (within the past month) had lower scores (role limitations due to physical health problems, bodily pain, general health perception and social function) than the general American population, whereas patients with a remote stone event (>1 month ago) had scores simi lar to the general population with the exception of general health perception 244, 245 . In addition to QOL evaluation for urolithiasis, it is also important to evaluate QOL in regard to management because some patients might require surgical treatment. The current guidelines for the management of uro lithiasis are based on the stonefree rates between the different surgical modalities but do not incorporate QOL as an additional end point. One study directly compared SWL, ureteroscopy and PCNL a few months after surgery to a control group using the SF36 questionnaire 248 . The global score after treatment was higher in the patients under going surgery than in controls for physical func tion, role limitations due to physical health problems, vitality, role limitations due to emotional problems and mental health; the only exception to this finding was for bodily pain, which was lower after treatment 248 . Two other studies did not find differences between patients who underwent surgical treatment and controls 249, 250 . When comparing the different surgical modalities, patients who underwent PCNL had worse scores in all QOL domains, except for bodily pain, whereas the patients who underwent SWL reported the highest QOL scores 248 . Furthermore, increasing numbers of surgical procedures were associated with lower QOL 244, 248 . Stent placement, often used at the end of the surgical pro cedure, has also been reported to impair QOL without a difference between ureteral and nephrostomy stents 244, [251] [252] [253] . In the case of residual fragments, one study found that fragments of >4 mm in size might affect QOL 254 . Finally, dietary changes and medical therapy have not been reported to affect QOL except for alkali therapy 244, 245 .
Outlook
John Wickham (a pioneer of stone surgery) once said at an early SWL congress -when he realized the conse quences of the procedure -that we had made an almost unbelievable journey from open surgery via minimally invasive techniques to noninvasive stone removal. Although this development reflected a giant step in stone treatment, his vision was that the final goal would be entirely medical. Three decades later, it is obvious that we still have a long way to go before that dream comes true.
Residual fragments in the kidney are frequently encountered, not only following SWL [255] [256] [257] but also after other minimally invasive procedures [258] [259] [260] [261] [262] . The course of residual fragments is variable, but their presence is problematic for both the patient and the treating physi cian and requires careful followup or, often, repeated intervention. Given that most residual fragments are composed of CaOx, will it be possible to accomplish fragment elimination by enzymatic dissolution with oxalate decarboxyl ase and formate dehydrogenase 262 ? Although such an approach certainly can be carried out by percutaneous irrigation in selected patients, the ques tion is whether or not it might be possible to incorporate the enzymes in stents or other intracorporeal devices with a slowrelease function. Furthermore, the medical advances of managing patients with stone disease have remained behind the times. The literature currently indicates a faint awaken ing interest in factors that are responsible for stone formation and recurrence preven tion 242, [263] [264] [265] . However, the enthu siasm among urologists to deal with metabolic and medical aspects of stone disease, nevertheless, is too weak.
Another therapy is that of inversion (head down) therapy, which is a procedure carried out after stone disintegration with the aim of favourably changing the position of the lower calyces. This step would facilitate fragment elimination by gravitation. The altered position of the kidneys is often combined with vibration on the body surface to add some kinetic energy. This treatment approach can be used in patients with residual fragments in the lower pole of the kidneys [266] [267] [268] [269] , although the results have been conflicting 270 .
In another recently published report, ultrasonic propulsion was used successfully to facilitate fragment elimination, which is a new and interesting concept 271 . Although promising, this technology is not US FDA approved and is being performed in patients only in experimental protocols. To facilitate fragment elimin ation, a pharmacological agent could be used to pro mote muscle contraction in the calyx. Poor local smooth muscle activity might, hypothetically, be associated with poor clearance of fragments. Whereas fragments from small disintegrated stones are relatively easily eliminated, fragments from large stones are not. A possible explan ation for this discrepancy is that the large stone in the calyx has hindered muscle contraction. This research area has not been addressed hitherto 272 . It is interesting to note that present treatment trends comprise relatively aggressive, albeit minimally inva sive, methods for fragment removal. Such a step is of course necessary in patients with infection stones and stones composed of uric acid, cystine and brushite, but the question is whether such procedures are necessary in asymptomatic patients with minor residual frag ments composed of CaOx. Given the high recurrence risk that these patients experience despite meticulous stone clearance, this is a pertinent question regarding overtreatment. In an epidemiological study 273 , a 10year recurrence risk of about 25% was shown for patients who had formed only one stone at the start of followup, but was approximately 70% for patients with more than one stone at the same point in time. The average recurrence risk for patients with calcium stones was estimated to be approximately 50% during a 10year period after their first stone episode 273 . Recent research has revived the role of Randall's plaques and plugs 88 . In the final process of CaOx stone formation, high supersaturation with CaOx and low pH seem to be important factors that need to be corrected 121 . The goal, therefore, should be to reduce the risk of precipi tation or growth of CaOx on the sur face of CaP 3, [274] [275] [276] (FIG. 8) . The formation of CaOx stones requires a complex interaction of nucleation of both CaP and CaOx, with subsequent growth and aggregation. Interference with the precipitation of these two essential crystal phases at different levels of the nephron seems necessary to arrest or counteract the formation of the most commonly encountered stones in patients.
Numerous recurrence preventive efforts for cal cium stone formation have been described and tested, but none have shown the capacity to definitely arrest stone formation. One contributing factor to insufficient success is the lack of longterm patient compliance 264 . Another important explanation is the shortage of means to counteract the initial precipitation of CaP 54 . With current treatment options, we are only addressing the final steps in the chain of abnormal crystallization events in idiopathic patients who form calcium stones. Whereas recurrence prevention in patients who are stone free can be accomplished by reducing supersaturation of CaOx in the final urine; how can we approach the remaining CaP deposits? Would it be possible to decrease CaP super saturation in the nephron urine and interstitial tissues with a shortterm intensive treatment and hope for nat ural elimination of CaP by the action of, for example, macrophages 49, 277 ? Or can we interfere with any other step in CaP precipitation that would eliminate this risk factor? In this regard, radiological improvements might enable the detection and quantification of papillary CaP deposits 278 . The initiation of stone formation in most patients is an occasional event. Accordingly, optimal compliance can only be expected with regimens based on strictly individualized analysis of risk factors and risk periods. The information obtained from 24hour urine collec tions and other longterm urine collections gives only rough average information on specific risk variables during the period. Indeed, imprecise data on urinary pH are the rule rather than the exception. Better analyti cal focus on periods assumed to represent particularly high risk is necessary. Such information can be obtained by combining a careful medical history with analysis of risk factors during periods when supersaturation with CaOx occurs simultaneously with low urinary pH. Such an approach might enable the design of individualized recurrence prevention 279 . Today, it is very attractive to remove kidney stones with flexible ureteroscopy 265 and, if that is not optimal, to use smaller and smaller instruments for percutane ous removal of smaller and smaller stones. However, it seems logical that for each treatment decision a bal ance is reached between the intention of the treatment and the efforts required to reach that goal. Active or pharmaco logical removal of residual fragments should be considered in view of the risk of the procedures and of the recurrence rate. There is no doubt that recurrence preventions need to be further developed, finetuned and used in an individually designed manner. With further increased understanding of the mechanisms behind stone formation, it is possible that some gen eral treatment can be prescribed for many patients with idiopathic calcium stone disease.
It stands to reason, however, that further progress in the management of patients who form stones cannot be made without a genuine interest and responsibility by urologists who regularly see these patients. The need for close interaction between stone removing and recur rence preventive procedures are absolute prerequisites for success. Basic as well as clinical research must have its focus on both aspects. In this regard, the urologist, during various endoscopic procedures, has a unique possibility to visually observe and record the clinical features of the pathology involved in stone formation. It cannot be too strongly emphasized that the optimal care of patients with stone disease is not only surgical, in its widest sense, but also medical. Oxidative stress in the proximal tubules might induce lipid peroxidation and damage to the brush border membrane at this level of the nephron. Released membrane fragments and vesicles containing phospholipids are considered important as promoters for both calcium phosphate (CaP) and calcium oxalate (CaOx) precipitation at supersaturation levels lower than those otherwise required for crystallization. Precipitation of CaOx higher in the nephron is only expected when very high concentrations of oxalate are available. Dilution of the urine at all levels of the nephron is most certainly associated with a reduced risk of intratubular, as well as interstitial, precipitation of CaP and CaOx. *Indicates that precipitation of CaOx at high nephron levels only occurs when very high concentrations of oxalate are available. AP, ion-activity product. 
